Transplantation of the highly human leukocyte antigen-sensitized patient: long-term outcomes and future directions

Transplantation Reviews

Volumn 20, Issue 3, 2006, Pages 146-156

  Peng, Alice ^a,b   Vo, Ashley ^a,b   Jordan, Stanley C ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; AUTOANTIBODY; CALCINEURIN INHIBITOR; CD19 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; FC RECEPTOR; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PLACEBO; PROTEIN A; RAPAMYCIN; RITUXIMAB; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY;

ANTIBODY TITER; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CLINICAL PROTOCOL; CLINICAL TRIAL; DESENSITIZATION; DRUG COST; DRUG POTENTIATION; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HISTOINCOMPATIBILITY; HLA MATCHING; HLA SYSTEM; HOSPITAL ADMISSION; HUMAN; IMMUNOADSORPTION; IMMUNOMODULATION; IMMUNOREGULATION; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; PLASMAPHERESIS; SENSITIZATION; TREATMENT OUTCOME;

EID: 33748071815     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2006.06.002     Document Type: Article

References (87)

1. OPTN/SRTR Annual Report 2004. http/ustransplant.org
2. Lucas D.P., Paparounis M.L., Myers L., Hart J.M., and Zachary A.A. Detection of HLA class I-specific antibodies by the QuikScreen enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 4 3 (1997) 252-257
3. Patel R., and Terasaki P.I. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 280 14 (1969) 735-739
4. Zachary A.A., and Hart J.M. Relevance of antibody screening and crossmatching in solid organ transplantation (1997), CRC Press, Boca Raton
5. Wolfe R.A., Ashby V.B., Milford E.L., Ojo A.O., Ettenger R.E., Agodoa L.Y., et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.[see comment]. N Engl J Med 341 23 (1999) 1725-1730
6. Zachary A.A., and Braun W.E. Calculation of a predictive value for transplantation. Transplantation 39 3 (1985) 316-318
7. Reinsmoen N, Herczyl W, Appel JI, Lima B, Rogers J, Burgess B, et al. Use of virtual crossmatch to optimize transplantation for sensitized heart and lung recipients. [submitted].
8. Claas F.H., de Waal L.P., Beelen J., Reekers P., Berg-Loonen P.V., de Gast E., et al. Transplantation of highly sensitized patients on the basis of acceptable HLA-A and B mismatches. Clinical Transplants (1989) 185-190
9. Montgomery R.A., Cooper M., Kraus E., Rabb H., Samaniego M., Simpkins C.E., et al. Renal transplantation at the Johns Hopkins Comprehensive Transplant Center. Clini Transpl (2003) 199-213
10. Reed E.F. Signal transduction via MHC class I molecules in endothelial and smooth muscle cells. Crit Rev Immunol 23 1-2 (2003) 109-128
11. Jordan S., Cunningham-Rundles C., and McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 3 6 (2003) 653-664
12. Tyan D.B., Li V.A., Czer L., Trento A., and Jordan S.C. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 57 4 (1994) 553-562
13. Jordan S.C., Quartel A.W., Czer L.S., Admon D., Chen G., Fishbein M.C., et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 66 6 (1998) 800-805
14. Jordan S.C., Vo A., Bunnapradist S., Toyoda M., Peng A., Puliyanda D., et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 76 4 (2003) 631-636
15. Jordan S.C., Tyan D., Stablein D., McIntosh M., Rose S., Vo A., et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15 12 (2004) 3256-3262
16. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345 10 (2001) 747-755
17. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. [see comment]. Science 291 5503 (2001) 484-486
18. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 2 (2003) 758-765
19. Magee J.C., Collins B.H., Harland R.C., Lindman B.J., Bollinger R.R., Frank M.M., et al. Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 96 5 (1995) 2404-2412
20. Lutz H.U., Stammler P., Bianchi V., Trueb R.M., Hunziker T., Burger R., et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 103 2 (2004) 465-472
21. Toyoda M., Pao A., Petrosian A., and Jordan S.C. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 3 2 (2003) 156-166
22. Kaneko Y., Nimmerjahn F., Madaio M., and Ravetch J. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 3 (2006) 789-797
23. Li N., Zhao M., Hilario-Vargas J., Prisayanh P., Warren S., Diaz L.A., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115 12 (2005) 3440-3450
24. Bohmig G.A., Exner M., Habicht A., Schillinger M., Lang U., Kletzmayr J., et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. [see comment]. J Am Soc Nephrol 13 4 (2002) 1091-1099
25. Williams J.M., Holzknecht Z.E., Plummer T.B., Lin S.S., Brunn G.J., and Platt J.L. Acute vascular rejection and accommodation: divergent outcomes of the humoral response to organ transplantation. Transplantation 78 10 (2004) 1471-1478
26. Abe J., Jibiki T., Noma S., Nakajima T., Saito H., and Terai M. Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. [see comment]. J Immunol 174 9 (2005) 5837-5845
27. Gill V., Doig C., Knight D., Love E., and Kubes P. Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. [see comment]. Circulation 112 13 (2005) 2031-2039
28. Turhan A., Jenab P., Bruhns P., Ravetch J.V., Coller B.S., and Frenette P.S. Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. Blood 103 6 (2004) 2397-2400
29. Jordan S., and Tyan D. Intravenous gamma globulin (IVIG) inhibits lymphocytotoxic antibody in vitro. J Am Soc Nephrol 2 (1991) 803
30. Glotz D., Antoine C., Julia P., Pegaz-Fiornet B., Duboust A., Boudjeltia S., et al. Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies. Transpl Int 17 1 (2004) 1-8
31. De Marco T., Damon L.E., Colombe B., Keith F., Chatterjee K., and Garovoy M.R. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 16 3 (1997) 360-365
32. Casadei D.H., del C.R.M., Opelz G., Golberg J.C., Argento J.A., Greco G., et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 71 1 (2001) 53-58
33. Luke P.P., Scantlebury V.P., Jordan M.L., Vivas C.A., Hakala T.R., Jain A., et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 72 3 (2001) 419-422
34. Wassmuth R., Hauser I.A., Schuler K., Erxleben H., Arnold M.L., Koelman C.A., et al. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. [see comment]. Transplantation 71 10 (2001) 1436-1442
35. Blasczyk R., Westhoff U., and Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. [see comment]. Lancet 341 8848 (1993) 789-790
36. Vo A., Lukovsky M., Toyoda M., Puliyanda D., Cam V., Bunnapradist S., et al. Safety and adverse event profiles of intravenous gammaglobulin (IVIG) products used for immunomodulation: a single center experience (abstract). Am J Transplant 4 Supp 8 (2004) 551
37. US Renal Data System. USRDS 2003 annual data report (2004), NIH, NIDDK, Bethesda (Md)
38. Zachary A.A., Montgomery R.A., Jordan S.C., Reinsmoen N., Claas F.H., and Reed E.F. Antibodies in transplantation: destroying old dogma, creating new paradigms. (in press). Tissue Antigens (2006)
39. Stegall M.D., Gloor J., Winters J.L., Moore S.B., and Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 2 (2006) 346-351
40. Jordan S.C., Vo A.A., Peng A., Toyoda M., and Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6 3 (2006) 459-466
41. Toyoda M., Petrosian A., Hilo L., Pao A., Rodich G., McIntosh M., et al. IVIG modulation of anti-HLA class 1 and class 2 antibody production in highly-sensitized patients is selective and not random: an analysis of the IGO2 study (abstract). Am J Transplant 4 Suppl 8 (2004) 583
42. Zachary A.A., Montgomery R.A., Ratner L.E., Samaniego-Picota M., Haas M., Kopchaliiska D., et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 76 10 (2003) 1519-1525
43. Zachary A.A., Montgomery R.A., Simpkins C.E., Warren D.S., and Leffell M.S. Impact of persistent, low-levels of donor-specific antibody (DSA) on renal transplants (abstract). Am J Transplant 5 Supplement 11 (2005) 245
44. Bach F.H., Turman M.A., Vercellotti G.M., Platt J.L., and Dalmasso A.P. Accommodation: a working paradigm for progressing toward clinical discordant xenografting. Transplant Proc 23 1 Pt 1 (1991) 205-207
45. Tanemura M., Yin D., Chong A., and Galili U. Differential immune response to carbohydrate epitopes on allo- and xenografts: implications for accommodation. Transplant Proc 32 5 (2000) 991-993
46. Kimball J.A., Pescovitz M.D., Book B.K., and Norman D.J. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 60 12 (1995) 1379-1383
47. Min L., Shuming J., Zheng T., Daxi J., Huiping C., Zhihong L., et al. Novel rescue therapy for C4d-positive acute humoral renal allograft rejection. Clin Transpl 19 1 (2005) 51-55
48. Jacobs J.P., Quintessenza J.A., Boucek R.J., Morell V.O., Botero L.M., Badhwar V., et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 78 5 (2004) 1703-1709
49. Zand M.S., Vo T., Huggins J., Felgar R., Liesveld J., Pellegrin T., et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79 11 (2005) 1507-1515
50. Colovai A.I., Vasilescu E.R., Foca-Rodi A., Kim-Schulze S., Hussaini N., D'Agati V.D., et al. Acute and hyperacute humoral rejection in kidney allograft recipients treated with anti-human thymocyte antibodies. Hum Immunol 66 5 (2005) 501-512
51. Nast CA, Peng A, Vo A, Jordan SC, Thymoglobulin induction therapy: a potential role in the pathogenesis of C4d (+) antibody-mediated rejection in highly-HLA sensitized patients desensitized with IVIG (abstract submitted to WTC 2006). 2006.
52. Pescovitz M.D., Book B.K., Henson S., Leapman S.B., Milgrom M.L., Kimball J., et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 3 4 (2003) 497-500
53. Toyoda M., Petrosyan A., Pao A., and Jordan S.C. Immunomodulatory effects of combination of pooled human gammaglobulin and rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplantation 78 8 (2004) 1134-1138
54. Ravandi F., and O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 5 1 (2005) 39-51
55. Hill P., Gagliardini E., Ruggenenti P., and Remuzzi G. Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrol Dial Transplant 20 8 (2005) 1741-1744
56. Cai J., Terasaki P.I., Bloom D.D., Torrealba J.R., Friedl A., Sollinger H.W., et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 78 6 (2004) 919-924
57. Bartosh S.M., Knechtle S.J., and Sollinger H.W. Campath-1H use in pediatric renal transplantation. Am J Transplant 5 6 (2005) 1569-1573
58. Pearl J.P., Parris J., Hale D.A., Hoffmann S.C., Bernstein W.B., McCoy K.L., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5 3 (2005) 465-474
59. Kirk A.D., Hale D.A., Mannon R.B., Kleiner D.E., Hoffmann S.C., Kampen R.L., et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76 1 (2003) 120-129
60. Squifflet J.P., De Meyer M., Malaise J., Latinne D., Pirson Y., and Alexandre G.P. Lessons learned from ABO-incompatible living donor kidney transplantation: 20 years later. Exp Clin Transplant 2 1 (2004) 208-213
61. Lorenz M., Regele H., Schillinger M., Kletzmayr J., Haidbauer B., Derfler K., et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 79 6 (2005) 696-701
62. Goodyear C.S., and Silverman G.J. B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies. Springer Semin Immunopathol 26 4 (2005) 463-484
63. Goodyear C.S., and Silverman G.J. Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Natl Acad Sci U S A 101 31 (2004) 11392-11397
64. Silverman G.J., Goodyear C.S., and Siegel D.L. On the mechanism of staphylococcal protein A immunomodulation. Transfusion 45 2 (2005) 274-280
65. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 2 (1994) 435-445
66. Piro L.D., White C.A., Grillo-Lopez A.J., Janakiraman N., Saven A., Beck T.M., et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. [see comment]. Ann Oncol 10 6 (1999) 655-661
67. Maloney D.G., Grillo-Lopez A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90 6 (1997) 2188-2195
68. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 8 (1998) 2825-2833
69. Sidner R.A., Book B.K., Agarwal A., Bearden C.M., Vieira C.A., and Pescovitz M.D. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 13 3 (2004) 55-62
70. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. [see comment]. N Engl J Med 350 25 (2004) 2572-2581
71. Albert D., Khan K., Stansberry S., Tsai D., and Eisenberg R. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus (poster). American College of Rheumatology Annual Scientific Meeting vol. LB9 (2003) 518
72. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 2 (2003) 455-459
73. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. [see comment]. Ann Rheum Dis 61 10 (2002) 883-888
74. Cooper N., Stasi R., Cunningham-Rundles S., Feuerstein M.A., Leonard J.P., Amadori S., et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125 2 (2004) 232-239
75. Gupta N., Kavuru S., Patel D., Janson D., Driscoll N., Ahmed S., et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 16 10 (2002) 2092-2095
76. Bearden C.M., Agarwal A., Book B.K., Sidner R.A., Gebel H.M., Bray R.A., et al. Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab. Hum Immunol 65 8 (2004) 803-809
77. Book B.K., Agarwal A., Milgrom A.B., Bearden C.M., Sidner R.A., Higgins N.G., et al. New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc 37 2 (2005) 640-642
78. Bearden C.M., Book B.K., Sidner R.A., and Pescovitz M.D. Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing. J Immunol Methods 300 1-2 (2005) 192-199
79. Kaplan I., Houp J.A., Montgomery R.A., Leffell M.S., Hart J.M., and Zachary A.A. A computer match program for paired and unconventional kidney exchanges. [erratum appears in Am J Transplant. 2005 ;5(10):2597 Note: Montgomery, Robert A [added]]. Am J Transplant 5 9 (2005) 2306-2308
80. Sawada T., Fuchinoue S., Kawase T., Kubota K., and Teraoka S. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transpl 18 3 (2004) 254-260
81. Kawagishi N., Satoh K., Enomoto Y., Akamatsu Y., Sekiguchi S., Fukumori T., et al. New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange. Transplant Proc 37 2 (2005) 1205-1206
82. Usuda M., Fujimori K., Koyamada N., Fukumori T., Sekiguchi S., Kawagishi N., et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation 79 1 (2005) 12-16
83. Sonnenday C.J., Warren D.S., Cooper M., Samaniego M., Haas M., King K.E., et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 4 8 (2004) 1315-1322
84. Tyden G., Kumlien G., Genberg H., Sandberg J., Lundgren T., and Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5 1 (2005) 145-148
85. Segev D.L., Simpkins C.E., Warren D.S., King K.E., Shirey R.S., Maley W.R., et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 5 10 (2005) 2570-2575
86. Gong Q., Ou Q., Ye S., Lee W.P., Cornelius J., Diehl L., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174 2 (2005) 817-826
87. Claas F.H., Witvliet M.D., Duquesnoy R.J., and Persijn G.G. Doxiadis, II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 78 2 (2004) 190-193